Nutrition and Dietary Supplements (Oct 2020)
The Potential Role of Xanthohumol in SARS-CoV-2 Treatment—Globally Accessible and Economically Viable
Abstract
Martyn Caplin,1 Luohai Chen2,3 1Gastroenterology, Royal Free Hospital, London, UK; 2Clinical Research, Royal Free Hospital, London, UK; 3Gastroenterology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, People’s Republic of ChinaCorrespondence: Martyn CaplinGastroenterology, Royal Free Hospital, London, UKTel +44 2078302867Email [email protected]: Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has resulted in significant global morbidity and mortality and there are a lack of effective therapies. There is a need for treatment which could be available for all in the global community, as well as within hospital, which is efficacious, affordable and safe. Xanthohumol from hop extract has been shown in vitro and in vivo to have antiviral properties against RNA and DNA viruses but also importantly anti-inflammatory properties against severe respiratory syndrome via inhibition of NFκB dependent pathways. We review the evidence for xanthohumol to be considered as a treatment for SARS-CoV-2 infection. We need an economic and globally available therapy and thinking beyond the traditional is important; thus, studies are warranted to assess efficacy of xanthohumol against SARS-CoV-2.Keywords: COVID-19, SARS-CoV-2, xanthohumol, hops
